Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes
- 1 April 2004
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (4), 547-550
- https://doi.org/10.1111/j.1538-7933.2004.00647.x
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin–sodium) in pediatric patientsThrombosis Research, 2003
- An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trialThrombosis Research, 2003
- Dosage, Anticoagulant, and Antithrombotic Effects of Heparin and Low-Molecular-Weight Heparin in the Treatment of Deep Vein ThrombosisSeminars in Thrombosis and Hemostasis, 1997
- Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding studyThe Journal of Pediatrics, 1996
- LOW MOLECULAR WEIGHT HEPARIN(S)British Journal of Haematology, 1995
- Hepatic uptake of a modified low molecular weight heparin in rats.Journal of Clinical Investigation, 1992
- Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the legThrombosis Research, 1992
- Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1992
- Delayed elimination of enoxaparine in patients with chronic renal insufficiencyThrombosis Research, 1991
- Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparinEuropean Journal of Clinical Pharmacology, 1990